<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159950</url>
  </required_header>
  <id_info>
    <org_study_id>I 250813</org_study_id>
    <secondary_id>NCI-2014-01184</secondary_id>
    <secondary_id>I 250813</secondary_id>
    <secondary_id>P30CA016056</secondary_id>
    <nct_id>NCT02159950</nct_id>
  </id_info>
  <brief_title>Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer</brief_title>
  <official_title>A Phase II Randomized Open Label Study of Sipuleucel-T vs. Sipuleucel-T and Tasquinimod in Patients With Metastatic Castrate-Resistant Prostate Cancer (CRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Active Biotech AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well sipuleucel-T with or without tasquinimod&#xD;
      works in treating patients with hormone-resistant prostate cancer that has spread to other&#xD;
      parts of the body. Vaccines made from a person's tumor cells and white blood cells may help&#xD;
      the body build an effective immune response to kill tumor cells. Tasquinimod may stop the&#xD;
      growth of prostate cancer by blocking the growth of new blood vessels necessary for tumor&#xD;
      growth. It is not yet known whether sipuleucel-T is more effective with or without&#xD;
      tasquinimod in treating prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether tasquinimod augments immune response to sipuleucel-T.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the safety and tolerability of the combination of sipuleucel-T and tasquinimod&#xD;
      in patients with castration-resistant metastatic prostate cancer.&#xD;
&#xD;
      II. To obtain preliminary evidence of the clinical benefit of the combination of sipuleucel-T&#xD;
      and tasquinimod; to include changes in prostate specific antigen (PSA) over time, and&#xD;
      duration of progression-free survival/overall survival.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive sipuleucel-T intravenously (IV) over 60 minutes on day 4. Treatment&#xD;
      repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      ARM II: Patients receive tasquinimod orally (PO) once daily (QD) beginning on day -14 and&#xD;
      sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in&#xD;
      the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod&#xD;
      treatment after day 42 until disease progression.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for up to 3&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Immune Response Assessed by IFN-g ELISPOT Specific for PA2024</measure>
    <time_frame>Baseline up to 50 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PSA Response</measure>
    <time_frame>Baseline to up to 3 years</time_frame>
    <description>PSA doubling time, PSA slope</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of PSA Response</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Toxicities Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The frequency of participants with toxicities will be tabulated by grade across all dose levels and courses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response (Arm 2 Only)</measure>
    <time_frame>Week 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rates (Partial or Complete)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Progression</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Effects of Tasquinimod on the Inhibition of Immune Cells</measure>
    <time_frame>Up to week 50</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Hormone-Resistant Prostate Cancer</condition>
  <condition>Metastatic Prostate Carcinoma</condition>
  <condition>Recurrent Prostate Carcinoma</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (sipuleucel-T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (tasquinimod, sipuleucel-T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (sipuleucel-T)</arm_group_label>
    <arm_group_label>Arm II (tasquinimod, sipuleucel-T)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sipuleucel-T</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (sipuleucel-T)</arm_group_label>
    <arm_group_label>Arm II (tasquinimod, sipuleucel-T)</arm_group_label>
    <other_name>APC8015</other_name>
    <other_name>APC8015 Vaccine</other_name>
    <other_name>PA2024 (PAP/GM-CSF)-Loaded Dendritic Cell Vaccine</other_name>
    <other_name>Provenge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tasquinimod</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (tasquinimod, sipuleucel-T)</arm_group_label>
    <other_name>ABR-215050</other_name>
    <other_name>TASQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic asymptomatic or minimally symptomatic castration-resistant prostate cancer&#xD;
             (CRPC) patients who are eligible for sipuleucel-T&#xD;
&#xD;
          -  Disease progression by PSA criteria (PSA Working Group Consensus Criteria Eligibility)&#xD;
             and/or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria&#xD;
&#xD;
          -  Life expectancy &gt;= 6 months&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Hemoglobin &gt;= 100 g/L (&gt;= 10 g/dL)&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mm^3&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x laboratory upper limit of normal&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x laboratory upper limit of normal&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x laboratory upper limit of normal or calculated creatinine&#xD;
             clearance of &gt;= 50 mL/min (please use institutional formula)&#xD;
&#xD;
          -  Prothrombin time (PT)/international normalized ratio (INR) =&lt; 1.5&#xD;
&#xD;
          -  Urine protein &lt; 1+; if &gt;= 1+, 24 hour urine protein should be obtained and should be &lt;&#xD;
             1000 mg&#xD;
&#xD;
          -  Central nervous system (CNS): no recent history (within 6 month) of cerebrovascular&#xD;
             accident, transient ischemic attacks, central nervous system or brain metastases&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Patient verbalizes the ability to swallow and retain oral medication&#xD;
&#xD;
          -  Subject or legal representative must understand the investigational nature of this&#xD;
             study and sign an Independent Ethics Committee/Institutional Review Board approved&#xD;
             written informed consent form prior to receiving any study related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received systemic steroids within 4 weeks prior to starting study&#xD;
             treatment&#xD;
&#xD;
          -  Patients who have received prior immunotherapies&#xD;
&#xD;
          -  History of therapy for an autoimmune disorder&#xD;
&#xD;
          -  Patients receiving any other investigational agents&#xD;
&#xD;
          -  Any medical condition that would preclude adequate evaluation of the safety and&#xD;
             toxicity of the study combination&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure (New York Association class II, III,&#xD;
             or IV), angina pectoris requiring nitrate therapy, recent myocardial infarction (less&#xD;
             than the last 6 months), cardiac arrhythmia, history of cerebrovascular accident (CVA)&#xD;
             within 6 months; no uncontrolled hypertension (defined as blood pressure of &gt; 160/90&#xD;
             mmHg) on medication or, history of peripheral vascular disease&#xD;
&#xD;
          -  Ongoing treatment with warfarin unless the international normalized ratio (INR) is&#xD;
             well controlled and below 4&#xD;
&#xD;
          -  History of psychiatric illness or social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  History of pancreatitis&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients receiving combination&#xD;
             antiretroviral therapy are ineligible&#xD;
&#xD;
          -  Systemic exposure to ketoconazole or other strong cytochrome P450, family 3, subfamily&#xD;
             A, polypeptide 4 (CYP3A4) isoenzyme inhibitors or inducers within 14 days prior to the&#xD;
             start of study treatment; systemic exposure to aminodarone is not allowed within 1&#xD;
             year prior to the start of study treatment&#xD;
&#xD;
          -  Ongoing treatment with sensitive cytochrome P450, family 1, subfamily A, polypeptide 2&#xD;
             (CYP1A2) substrate or CYP1A2 substrate with narrow therapeutic range at the start of&#xD;
             study treatment&#xD;
&#xD;
          -  Ongoing treatment with CYP3A4 substrate with narrow therapeutic range at the start of&#xD;
             study treatment&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to day 1 of therapy&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements&#xD;
&#xD;
          -  Any condition which in the investigator's opinion deems the patient an unsuitable&#xD;
             candidate to receive study drug&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saby George</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>June 9, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <results_first_submitted>February 10, 2016</results_first_submitted>
  <results_first_submitted_qc>April 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2016</results_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Sipuleucel-T)</title>
          <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
          <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated and eligible patients</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Sipuleucel-T)</title>
          <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
          <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="75.4" spread=".70"/>
                    <measurement group_id="B3" value="75.4" spread=".70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Immune Response Assessed by IFN-g ELISPOT Specific for PA2024</title>
        <time_frame>Baseline up to 50 weeks</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Immune Response Assessed by IFN-g ELISPOT Specific for PA2024</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PSA Response</title>
        <description>PSA doubling time, PSA slope</description>
        <time_frame>Baseline to up to 3 years</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PSA Response</title>
          <description>PSA doubling time, PSA slope</description>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of PSA Response</title>
        <time_frame>Up to 3 years</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of PSA Response</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Toxicities Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4</title>
        <description>The frequency of participants with toxicities will be tabulated by grade across all dose levels and courses.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>All treated and eligible patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Toxicities Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4</title>
          <description>The frequency of participants with toxicities will be tabulated by grade across all dose levels and courses.</description>
          <population>All treated and eligible patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response</title>
        <time_frame>Week 6</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response</title>
        <time_frame>Week 10</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response</title>
        <time_frame>Week 26</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response</title>
        <time_frame>Week 50</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response (Arm 2 Only)</title>
        <time_frame>Week 0</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response (Arm 2 Only)</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rates (Partial or Complete)</title>
        <time_frame>Up to 3 years</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rates (Partial or Complete)</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>Up to 3 years</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>Up to 3 years</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PSA Progression</title>
        <time_frame>Up to 3 years</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA Progression</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effects of Tasquinimod on the Inhibition of Immune Cells</title>
        <time_frame>Up to week 50</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Tasquinimod on the Inhibition of Immune Cells</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Sipuleucel-T)</title>
          <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
          <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sipuleucel-T: Given IV&#xD;
Tasquinimod: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="23" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="30" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="57" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="27" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="18" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="13" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="24" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the study's early closure, as a result of lack of funding, target accrual was not reached and no statistical inference of the primary and secondary aims were carried forth.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Administrator, Compliance - Clinical Research Services</name_or_title>
      <organization>Roswell Park Cancer Institute</organization>
      <phone>716-845-2300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

